Table 2.
Univariate and multivariate Cox regression analysis of factors independently associated with overall survival
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| 3-Year OS (%) | 5-Year OS (%) | p | HR (95% CI) | p | |
| ASA classification | |||||
|
1 2 3 |
75.9 80.6 40.8 |
64.3 70.8 30.6 |
< 0.0001 |
Ref. 4.5 (1.96–10.1) |
0.00003 |
| Neoadjuvant chemotherapy | |||||
|
No Yes |
81.4 54.9 |
70.4 47.8 |
0.001 |
Ref. 2.2 (1.36–3.58) |
0.002 |
| Gastrectomy extent | |||||
|
Distal Total |
80.5 57.7 |
70.7 45.8 |
< 0.0001 | ns | |
| Lymphadenectomy extent | |||||
|
D1 D2 |
60 78.4 |
46.5 68.9 |
0.006 |
Ref. 0.35 (0.2–0.6) |
0.010 |
| Radicality on pathology | |||||
|
R0 R1 |
0.003 |
Ref. 3.4 (1.2–10) |
0.028 | ||
| Margins adequacy (JGCA) | |||||
|
Adequate Inadequate |
82.7 55.5 |
73.2 43.3 |
< 0.0001 |
Ref. 2.35 (1.5–3.7) |
0.0003 |
| Margins adequacy (NCCN) | |||||
|
Adequate Inadequate |
81 65 |
72.8 51 |
< 0.0001 | – | |
| Margins adequacy (ESMO) | |||||
|
Adequate Inadequate |
78.9 73.9 |
71.3 62.1 |
0.110 | ||
| Tumor location | |||||
|
Upper 1/3 Mid 1/3 Lower 1/3 |
62.2 76.9 76.9 |
42.7 66.1 68.4 |
0.006 | ns | |
| pT stage | |||||
|
T1 T2 T3 T4 |
92.8 80.8 66.4 55.8 |
81.1 80.8 53.7 47.4 |
< 0.0001 | ns | |
| pN stage | |||||
|
N0 N1 N2 N3a N3b |
87.7 85.7 58.7 58.6 48.9 |
77.3 83.1 45.2 49,.9 19.6 |
< 0.0001 |
Ref. 0.93 (0.44–1.9) 2.2 (1.2–3.1) 3.4 (1.7–6.6) 4.8 (2.3–10.3) |
0.00003 |
| pTNM stage | |||||
|
I II III |
92.6 79.2 56 |
83.8 70.8 42.9 |
< 0.0001 | – | |
p values < 0.05 are indicated in bold
OS overall survival, 95% CI 95% confidence interval, HR hazard ratio, ASA American Society of Anesthesiology, JGCA Japanese Gastric Cancer Association, NCCN National Comprehensive Cancer Network, ESMO European Society of Medical Oncology